Ken Griffin Apellis Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 112,200 shares of APLS stock, worth $2.73 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

112,200

Previous 134,300 16.46%

Holding current value

$2.73 Million

Previous $4.29 Million 42.75%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$21.87 - $34.63 $2.44 Million - $3.87 Million	111,673 Added 99.33%	224,096 $4.9 Million
Q4 2024 Feb 14, 2025	SELL	$26.18 - $35.42 $2.24 Million - $3.04 Million	-85,710 Reduced 43.26%	112,423 $3.59 Million
Q3 2024 Nov 14, 2024	BUY	$28.84 - $41.15 $1.28 Million - $1.82 Million	44,242 Added 28.75%	198,133 $5.71 Million
Q2 2024 Aug 14, 2024	SELL	$38.07 - $59.71 $39.3 Million - $61.6 Million	-1,032,191 Reduced 87.03%	153,891 $5.9 Million
Q1 2024 May 15, 2024	BUY	$55.39 - $72.47 $49.9 Million - $65.3 Million	900,965 Added 316.0%	1,186,082 $69.7 Million
Q4 2023 Feb 14, 2024	BUY	$37.14 - $64.82 $10 Million - $17.5 Million	270,370 Added 1833.39%	285,117 $17.1 Million
Q3 2023 Nov 14, 2023	SELL	$23.65 - $89.22 $12.2 Million - $45.8 Million	-513,825 Reduced 97.21%	14,747 $560,000
Q2 2023 Aug 14, 2023	BUY	$76.68 - $93.31 $27.2 Million - $33.1 Million	354,512 Added 203.67%	528,572 $48.2 Million
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $7.86 Million - $11.3 Million	168,791 Added 3203.47%	174,060 $11.5 Million
Q4 2022 Feb 14, 2023	SELL	$43.24 - $61.04 $1.85 Million - $2.62 Million	-42,892 Reduced 89.06%	5,269 $272,000
Q3 2022 Nov 14, 2022	SELL	$44.76 - $69.66 $6.68 Million - $10.4 Million	-149,298 Reduced 75.61%	48,161 $3.29 Million
Q2 2022 Aug 15, 2022	SELL	$35.07 - $59.21 $8.13 Million - $13.7 Million	-231,793 Reduced 54.0%	197,459 $8.93 Million
Q1 2022 May 16, 2022	SELL	$35.46 - $54.12 $18.6 Million - $28.4 Million	-524,479 Reduced 54.99%	429,252 $21.8 Million
Q4 2021 Feb 14, 2022	SELL	$30.74 - $49.16 $27.8 Million - $44.5 Million	-904,701 Reduced 48.68%	953,731 $45.1 Million
Q3 2021 Nov 15, 2021	BUY	$31.4 - $69.84 $47.3 Million - $105 Million	1,505,416 Added 426.44%	1,858,432 $61.3 Million
Q2 2021 Aug 16, 2021	BUY	$40.9 - $64.9 $12.3 Million - $19.5 Million	300,464 Added 571.75%	353,016 $22.3 Million
Q1 2021 May 17, 2021	SELL	$40.8 - $57.39 $56.5 Million - $79.5 Million	-1,384,394 Reduced 96.34%	52,552 $2.26 Million
Q4 2020 Feb 16, 2021	SELL	$30.79 - $57.2 $23.6 Million - $43.8 Million	-765,312 Reduced 34.75%	1,436,946 $82.2 Million
Q3 2020 Nov 16, 2020	BUY	$25.89 - $33.65 $21.6 Million - $28 Million	832,498 Added 60.78%	2,202,258 $66.4 Million
Q2 2020 Aug 14, 2020	BUY	$24.8 - $38.49 $15.7 Million - $24.4 Million	634,920 Added 86.4%	1,369,760 $44.7 Million
Q1 2020 May 15, 2020	BUY	$17.91 - $44.33 $3.2 Million - $7.91 Million	178,480 Added 32.08%	734,840 $19.7 Million
Q4 2019 Feb 14, 2020	SELL	$22.1 - $30.8 $1.89 Million - $2.63 Million	-85,360 Reduced 13.3%	556,360 $17 Million
Q2 2019 Aug 14, 2019	SELL	$18.0 - $25.34 $5.46 Million - $7.69 Million	-303,464 Reduced 32.11%	641,720 $16.3 Million
Q1 2019 May 15, 2019	BUY	$12.81 - $19.82 $11.5 Million - $17.7 Million	894,915 Added 1780.25%	945,184 $0
Q4 2018 Feb 14, 2019	SELL	$11.47 - $18.71 $154,191 - $251,518	-13,443 Reduced 21.1%	50,269 $663,000
Q3 2018 Nov 13, 2018	BUY	$16.57 - $21.03 $869,013 - $1.1 Million	52,445 Added 465.47%	63,712 $0
Q2 2018 Aug 10, 2018	BUY	$19.63 - $30.0 $221,171 - $338,010	11,267 New	11,267 $0

Others Institutions Holding APLS

# of Institutions

285

Shares Held

125M

Call Options Held

921K

Put Options Held

761K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.67B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account